Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Risk of death during the 2020 UK COVID-19 epidemic among people with rare autoimmune diseases compared to the general population. A whole-population study in England, using data from the National Disease Registration Service and the Registration of Complex Rare Diseases - exemplars in Rheumatology (RECORDER) project

Emily Peach, Megan Rutter, Peter Lanyon, Matthew J Grainge, Richard Hubbard, Jeanette Aston, Mary Bythell, Sarah Stevens, Fiona Pearce
doi: https://doi.org/10.1101/2020.10.09.20210237
Emily Peach
1Division of Epidemiology and Public Health, University of Nottingham UK
Roles: Research Fellow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan Rutter
1Division of Epidemiology and Public Health, University of Nottingham UK
Roles: Clinical Research Fellow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Lanyon
2Nottingham University Hospitals NHS Trust, Nottingham, UK
Roles: Consultant Rheumatologist and Honorary Clinical Associate Professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew J Grainge
1Division of Epidemiology and Public Health, University of Nottingham UK
Roles: Associate Professor in Medical Statistics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Hubbard
1Division of Epidemiology and Public Health, University of Nottingham UK
Roles: Professor of Epidemiology and Honorary Respiratory Consultant
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeanette Aston
3National Disease Registration Service, Public Health England
Roles: NCARDRS rare disease data liaison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Bythell
3National Disease Registration Service, Public Health England
Roles: NCARDRS Head of Rare Disease
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Stevens
3National Disease Registration Service, Public Health England
Roles: Interim Deputy Director
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona Pearce
1Division of Epidemiology and Public Health, University of Nottingham UK
Roles: Clinical Associate Professor of Rheumatology Epidemiology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Fiona.Pearce@nottingham.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives To quantify the risk of death among people with rare autoimmune rheumatic diseases (RAIRD) during the UK 2020 COVID-19 epidemic compared with baseline risk and the risk of death in the general population during COVID-19.

Design A cohort study using data from the National Congenital Anomaly and Rare Disease Registration Service (NCARDRS). We used ONS published data for general population mortality rates.

Setting Hospital Episode Statistics for England 2003 onwards, and linked data from the NHS Personal Demographics Service.

Participants 168,691 people with RAIRD who were alive on 1 March 2020. Their median age was 61.7 (IQR 41.5-75.4) years, and 118,379 (70.2%) were female. Our case ascertainment methods had a positive predictive value >85%.

Main outcome measure Age-standardised mortality rates for all-cause death. Secondary outcome measures were age-sex standardised mortality rates, and age-stratified mortality rates.

Results 1,815 (1.1%) participants died during March and April 2020. The age-standardised mortality rate (ASMR) among people with RAIRD (3669.3, 95% CI 3500.4-3838.1 per 100,000 person-years) was 1.44 (95% CI 1.42-1.45) times higher than the average ASMR during the same months of the previous 5 years, whereas in the general population of England it was 1.38 times higher. Compared to the general population, the age-specific mortality rates in people with RAIRD compared to the pre-COVID rates were higher from the age of 35 upwards, whereas in the general population the increased risk began from age 55 upwards. Sex-specific mortality rates were similar in males and females, whereas pre-COVID women with rare autoimmune rheumatic diseases had lower mortality rates. This means women had a greater increase in mortality rates during COVID-19 compared to men.

Conclusions The risk of all-cause death is more prominently raised during COVID-19 among people with RAIRD than among the general population. We urgently need to quantify how much risk is due to COVID-19 infection and how much is due to disruption to healthcare services, in order to inform better guidance about shielding, access to healthcare and vaccine priorities for people with rare diseases.

What is already known on this topic?People with rare diseases often suffer worse health outcomes than people with more common diseases. Little is known about the risks to people with rare diseases during COVID-19. The OPENSAFELY study found people with common autoimmune diseases were at little increased risk due to COVID-19.

What this study adds This is the first study to quantify the risk of death among people with rare autoimmune rheumatic diseases (RAIRD) during COVID-19.

  • When compared to before COVID-19, the risk of dying during COVID-19 for people with a rare autoimmune rheumatic disease increased from age 35 years onwards, whereas in the general population it increased from the age of 55 onwards.

  • When adjusted for age, the risk of dying during COVID-19 was similar for men and women with a rare autoimmune rheumatic disease, whereas before COVID-19 women with rare autoimmune rheumatic diseases had a lower risk of death. This means women had a greater increase in their risk of death during COVID-19 compared to men.

  • For people of working age with rare autoimmune rheumatic diseases, the risk of dying during the COVID-19 pandemic was similar to that of someone 20 years older in the general population.

We urgently need to quantify how much risk is due to COVID-19 infection and how much due to disruption to healthcare services to inform better shielding advice, prioritisation of healthcare services, and vaccine priorities for people with rare diseases.

Competing Interest Statement

EP, FP and PCL are recipients of a grant from Vifor pharma. Vifor pharma had no influence on the design, conduct or interpretation of this study.

Funding Statement

MR is funded by Vasculitis UK (patient charity) and the British Society for Rheumatology. EP, FP and PCL are recipients of a grant from Vifor pharma. Vifor pharma had no influence on the design, conduct or interpretation of this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study received a favourable opinion from the Camden and Kings Cross Research Ethics Committee, study reference 20/HRA/2076, on 18 June 2020. Data were accessed and processed under section 251 permission granted to NCARDRS CAG 10-02(d)/2015).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Emily.peach{at}nottingham.ac.uk

  • Megan.Rutter{at}nottingham.ac.uk

  • Peter.Lanyon{at}nottingham.ac.uk

  • Matthew.Grainge{at}nottingham.ac.uk

  • Richard.Hubbard{at}nottingham.ac.uk

  • Jeanette.Aston{at}phe.gov.uk

  • Mary.Bythell{at}phe.gov.uk

  • Sarah.Stevens{at}phe.gov.uk

  • Fiona.Pearce{at}nottingham.ac.uk

  • Title updated, Key messages and Abstract results updated, Patient and Public involvement statement updated, Funding statement updated.

Data Availability

NCARDRS data are available to all who have a legal basis to access them. Further information is available at by application to Public Health England Office for data release (Available from www.gov.uk/government/publications/accessing-public-health-england-data/about-the-phe-odr-and-accessing-data [cited 2020 Oct 9])

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 16, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Risk of death during the 2020 UK COVID-19 epidemic among people with rare autoimmune diseases compared to the general population. A whole-population study in England, using data from the National Disease Registration Service and the Registration of Compl…
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Risk of death during the 2020 UK COVID-19 epidemic among people with rare autoimmune diseases compared to the general population. A whole-population study in England, using data from the National Disease Registration Service and the Registration of Complex Rare Diseases - exemplars in Rheumatology (RECORDER) project
Emily Peach, Megan Rutter, Peter Lanyon, Matthew J Grainge, Richard Hubbard, Jeanette Aston, Mary Bythell, Sarah Stevens, Fiona Pearce
medRxiv 2020.10.09.20210237; doi: https://doi.org/10.1101/2020.10.09.20210237
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Risk of death during the 2020 UK COVID-19 epidemic among people with rare autoimmune diseases compared to the general population. A whole-population study in England, using data from the National Disease Registration Service and the Registration of Complex Rare Diseases - exemplars in Rheumatology (RECORDER) project
Emily Peach, Megan Rutter, Peter Lanyon, Matthew J Grainge, Richard Hubbard, Jeanette Aston, Mary Bythell, Sarah Stevens, Fiona Pearce
medRxiv 2020.10.09.20210237; doi: https://doi.org/10.1101/2020.10.09.20210237

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Rheumatology
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (419)
  • Anesthesia (97)
  • Cardiovascular Medicine (894)
  • Dentistry and Oral Medicine (166)
  • Dermatology (101)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
  • Epidemiology (8744)
  • Forensic Medicine (4)
  • Gastroenterology (403)
  • Genetic and Genomic Medicine (1845)
  • Geriatric Medicine (175)
  • Health Economics (386)
  • Health Informatics (1281)
  • Health Policy (642)
  • Health Systems and Quality Improvement (489)
  • Hematology (206)
  • HIV/AIDS (387)
  • Infectious Diseases (except HIV/AIDS) (10520)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (216)
  • Neurology (1744)
  • Nursing (100)
  • Nutrition (264)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (457)
  • Oncology (959)
  • Ophthalmology (279)
  • Orthopedics (107)
  • Otolaryngology (174)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (262)
  • Pediatrics (553)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1836)
  • Public and Global Health (3963)
  • Radiology and Imaging (649)
  • Rehabilitation Medicine and Physical Therapy (340)
  • Respiratory Medicine (532)
  • Rheumatology (214)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (165)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (105)
  • Urology (78)